- Home
- IMMP vs PAYS Comparison
IMMP vs PAYS Comparison
Compare IMMP & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- PAYS
- Stock Information
- Founded
- IMMP 1987
- PAYS 2001
- Country
- IMMP Australia
- PAYS United States
- Employees
- IMMP N/A
- PAYS N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- PAYS Business Services
- Sector
- IMMP Health Care
- PAYS Consumer Discretionary
- Exchange
- IMMP Nasdaq
- PAYS Nasdaq
- Market Cap
- IMMP 256.1M
- PAYS 276.1M
- IPO Year
- IMMP N/A
- PAYS 1998
- Fundamental
- Price
- IMMP $1.90
- PAYS $5.25
- Analyst Decision
- IMMP Buy
- PAYS Strong Buy
- Analyst Count
- IMMP 1
- PAYS 4
- Target Price
- IMMP $7.00
- PAYS $8.06
- AVG Volume (30 Days)
- IMMP 128.2K
- PAYS 479.3K
- Earning Date
- IMMP 02-22-2026
- PAYS 11-12-2025
- Dividend Yield
- IMMP N/A
- PAYS N/A
- EPS Growth
- IMMP N/A
- PAYS N/A
- EPS
- IMMP N/A
- PAYS 0.13
- Revenue
- IMMP $3,306,742.00
- PAYS $74,879,428.00
- Revenue This Year
- IMMP N/A
- PAYS $35.44
- Revenue Next Year
- IMMP N/A
- PAYS $21.93
- P/E Ratio
- IMMP N/A
- PAYS $40.18
- Revenue Growth
- IMMP 31.28
- PAYS 32.61
- 52 Week Low
- IMMP $1.32
- PAYS $1.80
- 52 Week High
- IMMP $2.71
- PAYS $8.88
- Technical
- Relative Strength Index (RSI)
- IMMP 56.87
- PAYS 48.74
- Support Level
- IMMP $1.68
- PAYS $4.95
- Resistance Level
- IMMP $1.95
- PAYS $5.53
- Average True Range (ATR)
- IMMP 0.09
- PAYS 0.33
- MACD
- IMMP 0.01
- PAYS 0.02
- Stochastic Oscillator
- IMMP 82.14
- PAYS 35.64
About IMMP Immutep Limited
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.